Phase 3 trial of olorofim versus AmBisome followed by standard of care for invasive aspergillosis

Phase 3, randomised, single-blind trial in invasive aspergillosis (IA) and aspergillosis comparing olorofim with AmBisome followed by standard of care (2 arms). Primary endpoint: All-cause mortality rate at Day 42. Started Jul 2021; status: active.